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T he major histocompatibility complex (MHC) locus, located on the short arm of human chromosome 6, encompasses a large cluster of genes coding for pro­tein products that are essential for immune recogni­tion and are characterized by the highest degree of 
diversity (polymorphism) among human genes. The human MHC 
locus is more commonly designated as HLA (human leukocyte anti­
gen) locus and encodes two major classes of protein products in­
volved in the immune response: HLA class I and HLA class II 
antigens (Fig 1). HLA class I antigens, which constitute the object of 
this review, can be subdivided into three subgroups, referred to as 
HLA-A, -B, and -c. Each of the three HLA class I loci comprises 
several genes (alleles) encoding a number of alloantigens. Because of 
the high degree of polymorphism of HLA class I antigens, the 
combination of different HLA-A, -B, and -C alleles on the two 
chromosomes 6 confers to each individual a virtually unique pheno­
type. 
Like their counterparts in other animal species, HLA class I anti­
gens are composed of a 45,000 Mr glycopolypeptide (heavy chain), 
non-covalently associated with the 11,600 Mr P2-microglobulin 
(P2-Jl.) (light chain) (Fig 2). MHC class I heavy chains are integral 
membrane proteins consisting of two amino-terminal extracellular 
polymorphic domains (a1 and aZ), followed by a constant extracel­
lular domain (a3), a hydrophobic transmembrane segment that an­
chors the molecule to the plasma membrane, and a carboxyl-ter­
minal cytoplasmic domain. The light chain (PrJl.) does not have a 
transmembrane region and is kept on the cell surface by virtue of its 
non-covalent association with the extracellular domains of HLA 
class I heavy chains. P2-Jl. molecules are essential for the transport of 
HLA class I heavy chains to the cell surface, as indicated by the lack 
of HLA class I antigen expression by cells that synthesize HLA class 
I heavy chains, but do not synthesize P2-Jl. [1]. The expression of 
HLA class I antigens is susceptible to modulation by cytokines like 
interferon (IFN) and tumor necrosis factor (TNF), which can in­
duce or upregulate the expression of these antigens. 
The association of P2-Jl. to HLA class I heavy chains markedly 
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changes their antigenic profile, as indicated by the very low number 
of antigenic determinants shared between P2-Jl.-associated and 
P2-Jl.-free HLA class I heavy chains. To the best of our knowledge, 
all polyclonal and monoclonal antibodies, elicited with P2-Jl.­
associated HLA class I heavy chains except two [2,3], fail to react 
with P2-Jl.-free HLA class I heavy chains. Conversely, antibodies 
elicited with isolated HLA class I heavy chains do not react with 
P2-J.l-associated HLA class I heavy chains. 
For many years it has been known that HLA class I antigens 
mediate and restrict lysis of target cells by cytotoxic T lymphocytes 
(for review, see [4]). The molecular basis of this phenomenon has 
been recently clarified: HLA class I alloantigens associate to peptides 
derived from the processing of endogenous proteins and present 
them to the T-cell receptor specific for a particular HLA class I 
alloantigen-peptide complex (combinatorial epitope) [5]. More­
over, an increasing body of experimental evidence accumulated 
during recent years suggests that MHC class I antigens play a 
broader role in cell economy than generally assumed. Thus, MHC 
class I antigens appear to modulate the proliferation of normal and 
malignant cells [6-10] as well as the lysis of malignant cells by 
natural killer (NK) cells (for review, see [11,12]). 
The potential role of altered HLA class I antigen expression in the 
escape of malignant cells from immune destruction and in their 
disordered proliferation has stimulated interest in the characteriza­
tion of HLA class I antigen expression by tumor cells. In the early 
investigations, the antigenic profile of established cell lines has been 
analyzed mostly with alloantisera to HLA class I allospecificities 
(for review, see [13]). More recently the availability of anti-HLA 
class I monoclonal antibodies has facilitated the application of im­
munohistochemical techniques to analyze surgically removed ma­
lignant lesions. These investigations have provided solid serologic 
and immunochemical evidence that the malignant transformation 
of human cells may be associated with abnormalities in HLA class I 
antigen expression such as 1} heterogeneity in the expression of 
HLA class I antigens among malignant cells within a lesion as well 
as among malignant lesions removed from a single patient at differ­
ent anatomic sites; 2} differential reactivity of malignant lesions 
with monoclonal antibodies recognizing determinants expressed on 
the HLA class I molecular complex and with anti -P2-Jl. monoclonal 
antibodies; 3} detection ofHLA class I antigens in the CYfoplasm of 
malignant cells; and/or 4} reduction or lack of HLA class I antigen 
expression on the cell surface of malignant cells. None of these 
changes is specific for malignant transformation; nevertheless, the 
potential effect of altered HLA class I antigen expression on the 
ability of the host's immune system to recognize malignant cells, 
the correlation observed between the expression of HLA class I 
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Figure 1. Organization of the HLA locus. HLA class I genes (A,B,C) are 
part of a large duster of related genetic elements, collectively designated 
as HLA locus, located on chromosome 6. Because two copies of each 
chromosome are present in every cell and HLA class I genes display a high 
degree of diversity (polymorphism), up to six different HLA class I anti­
gens can be expressed by each individual (codominant expression of HLA 
class I genes). In contrast, P2-P. is encoded by a non-polymorphic, single­
copy gene on chromosome 15; therefore, two identical copies of B2m gene 
are expressed by each cell. 
antigens in malignant lesions, and the clinical course of certain 
malignant diseases [14,15] have stimulated interest in the character­
ization of the molecular mechanisms underlying these abnormali­
ties and in their functional implications. These studies, which have 
been facilitated by the broad use of recombinant DNA technology 
during recent years, may suggest novel therapeutic approaches to 
malignant diseases that rely on the correction of abnormalities in 
HLA class I antigen expression, if these abnormalities do indeed 
play a role in the pathogenesis and clinical course of malignant 
diseases. 
In this paper we will describe the types of alterations in HLA class 
I antigen expression that have been identified in melanoma cells and 
discuss the molecular mechanisms underlying these alterations as 
well as the associated functional implications. 
LACK OF HLA CLASS I ANTIGEN EXPRESSION BY 
MELANOMA CELLS 
Immunohistochemical staining with monoclonal antibodies to 
monomorphic determinants shared by HLA-A, -B, and -C antigens 
fails to detect HLA class I antigens in about 30% of the surgically 
removed melanoma lesions tested (for review, see [16]). The loss of 
HLA class I antigens, which has been documented both in primary 
and metastatic lesions, correlates neither with the histopathologic 
characteristics of the lesions nor with the expression of melanoma­
associated antigens [17]. A relationship has been found only be­
tween the expression of HLA class I and HLA class II antigens, 
because the latter are expressed mostly by melanoma cells that ex­
press HLA class I antigens. In fact, only melanoma cells that lack 
HLA class I antigens have been found rarely to express HLA class II 
antigens [15,18]. 
To the best of our knowledge, only the melanoma cells lines 
FO-l and SK-MEL-33 have been found to completely lack HLA 
class I antigen expression and not to acquire these antigens follow­
ing incubation with cytokines [19,20]. In both cell lines, the lack of 
HLA class I antigen expression is caused by structural abnormalities 
of PdJ.. However, the molecular lesions are different in the two 
cases. In FO-l cells the B2m gene is not transcribed because of a 
deletion encompassing part of the 5' flanking region, the first exon, 
and at least part of the first intron. In SK-MEL-33 cells, deletion of a 
guanosine at position 323 corresponding to codon 76 of P2-P. 
mRNA causes a reading frameshift with a subsequent introduction 
of a stop codon at codon 82 (54 bases upstream from the normal 
position of the stop codon). This mutation results in the translation 
of a truncated protein that is 18 amino acids shorter than the wild­
type protein. Furthermore, the reading frameshift changes codons 
76 to 81 and the corresponding amino acids. These changes include 
replacement with alanine of one of the two cysteines that are in­
volved in the intrachain disulfide bond in P2-P.. The loss of this 
disulfide bond is likely to have a dramatic effect on the structure of 
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Figure 2. Schematic representation of synthesis and cell surface expres­
sion of HLA class I antigens. Boxes, exons of HLA class I heavy chain and 
B2m genes, i.e., DNA sequences that are transcribed into mRNA; open 
boxes, DNA sequences coding for a protein product; solid boxes (at each end 
of the gene), DNA sequences that are transcribed into mRNA, but are not 
coding for a protein product. L, the sequence coding for the leader peptide 
(see below). a1, a2, a3, the exons coding for each of the three extracellular 
domains of HLA class I heavy chain. TM and CYT, the exons coding for 
the transmembrane and cytoplasmic portion of class I heavy chain, respec­
tively. 5'UT and 3'UT (5' and 3' untranslated, respectively), parts of 
mRNA molecule that are not translated into protein. Following transla­
tion of mRNA into precursor protein, the leader peptide at the NH2 
terminus of both HLA class I heavy chain and P2-P. is cleaved off, releasing 
the mature protein. Shortly after their synthesis, HLA class I heavy chains 
assembly non-covalently with P2-P. in the endoplasmic reticulum. This 
association is stabilized by the binding of peptides, nine to ten amino acid 
residues in length, that are derived from the cleavage of endogenous 
proteins. The binding of peptide to the HLA class I heavy chain-P2-p. 
complex makes it competent for transport to the cell surface. 
PdJ. in SK-MEL-33 cells, because P2-P. has been shown to have a 
p-sandwich structure composed of two antiparallel p-pleated sheets 
connected by a disulfide bond [21]. The breakage of this connection, 
the change in six amino acids, and the loss of 18 amino acids in the 
carboxyl-terminal of P2-P. are likely to cause a drastic change in the 
spatial configuration of the polypeptide, which may account for the 
inability of the truncated P2-P. synthesized by SK-MEL-33 cells to 
associate with HLA class I heavy chains. Consistent with this inter­
pretation, we found that both FO-l and SK-MEL-33 cells express 
HLA class I antigens following transfection with a wild-type B2m 
gene. 
SELECTIVE LOSS OF THE GENE PRODUCTS OF 
HLA-A, -B, AND -C LOCI BY MELANOMA CELLS 
A limited number of surgically removed melanoma lesions have 
been analyzed for the expression of the gene products of HLA-A, 
-B, and -C loci. This reflects, at least in part, the availability of only a 
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Table L Effect of IFN-)I on the Differential Reactivity of Cultured Melanoma Cells MM-AN 
with Anti-HLA-A and Anti-HLA-B Monoclonal Antibodies" 
Monoclonal Antibodies 
Cell line IFN-" VF19LL67 H2-89-1 Q6/64 TP25.99 05/13 CL203.4 
MM-AN 0.431 0.069 0.070 0.305 0.056 0.233 
+ 0.646 0.270 0.302 0.407 0.043 0.542 
MM-RU 0.303 0.208 0.218 0.218 0.057 0.058 
+ 0.905 0.587 0.615 0.650 0.080 0.067 
• Cultured me1anoma cells MM-AN were incubated with lPN-y (1000 U /mJ) for 72 h. Control ceUs were incubated under the same experimental conditions, but without 
lPN-y. At the end of the incubation, cells were washed and tested with anti-HLA-A monoclonal antibody VF19LL67 and anti-HLA-B monoclonal antibody H2-89-1 and 
06/64 in BUSA. Anti-HLA class I monoclonal antibody TP2S.99, anti-HLA class D monoclonal antibody Q5/13, and anti-ICAM-l monoclonal antibody CL203.4, and 
cultured human melanoma cells MM-RU were used as contro1s. 
few monoclonal antibodies that display a preferential reactivity 
with HLA-A, -B, or -C antigens. Versteeg et al [22] have identified 
two surgical lesions with a selective lack ofHLA-B antigen expres­
sion. Furthermore, they have identified three melanoma cell lines 
with reduced HLA-B antigen expression [22] and we have identi­
fied one (Table I). In all four melanoma cell lines, the level of the 
selectively reduced HLA-B locus gene products was enhanced by 
IFN-)l. Although we have not determined the molecular abnormal­
ity(ies) that underlies the reduced HLA-B antigen expression by the 
melanoma cell line MM-AN, Versteeg et al [22] have reported that 
the downregulation of HLA-B antigen expression in their three 
melanoma cell lines is a consequence of decreased HLA-B gene 
transcription caused by an overexpression of the c-myc oncogene. 
SELECTIVE LOSS OF HLA CLASS I ALLOSPECIFICITIES 
BY MELANOMA CELLS 
The availability of monoclonal antibodies specific for certain HLA 
class I alloantigens has made it possible to analyze the expression of a 
limited number of HLA class I allospecificities by melanoma cells, 
because the conventional anti-HLA class I alloantisera are not suit­
able for immunohistochemical staining of surgically removed mela­
noma lesions and for typing of melanoma cells in culture. Natali et al 
[23] have described a selective reduction or loss ofHLA-A2 antigens 
in three surgically removed melanoma lesions that express mono­
morphic determinants shared by HLA-A, -B, and -C antigens. We 
have identified the selective loss of HLA-A2 antigens by the mela­
noma cell lines M2 and M3 [24]. The lack of HLA-A2 antigen 
expression on the cell membrane is associated with the lack of 
HLA-A2 mRNA. Neither M2 nor M3 cells acquired HLA-A2 anti­
gens following incubation with IFN-a or IFN-)l. However, HLA­
A2 antigen expression could be restored on M2 cells following 
transfection with a wild-type HLA-A2 gene [24]. These studies 
indicated that M2 melanoma cells are not inherendy unable to ex­
press the HLA-A2 antigen, and suggested that the block in the 
expression of the endogenous HLA-A2 gene occurred at the tran­
scriptional level. 
FUNCTIONAL IMPLICATIONS OF ALTERED HLA 
CLASS I ANTIGEN EXPRESSION BY MELANOMA CELLS 
The HLA class I antigen-restricted lysis of melanoma cells by cyto­
toxic T cells and inhibition of lysis by anti-HLA class I monoclonal 
antibodies (for review, see [25,261) suggest that abnormalities in 
HLA class I antigen expression wilf affect the susceptibility of mela­
noma cells to lysis by cytotoxic T cells. Nevertheless, formal proof 
that this is the case is not available in the literature. In our own 
experience, inconsistent results were obtained. Specifically, re-ex­
pression ofHLA-A2 antigen by the human melanoma cell line M2 
was associated with only partial restoration of immunologic recog­
nition by autologous T lymphocytes [24]. These experimental re­
sults suggest that additional factors, besides expression ofHLA class 
I antigens, play a major role in the lysis of melanoma cells by cyto­
toxic T cells that recognize melanoma associated antigens. 
Conflicting information is available about the role ofHLA class I 
antigens in NK. cell-mediated lysis of melanoma cells. Lobo and 
Spencer [27] have found no increase in the extent of NK. cell-me­
diated lysis of SK-MEL-1 melanoma cells following incubation 
with anti -HLA class I monoclonal antibodies, although these anti­
bodies enhance NK. cell-mediated lysis of other types of human 
malignant cells. Versteeg et al [28] have observed an increased sus­
ceptibility to NK cell-mediated lysis of an HLA class I-negative 
variant derived from the melanoma cell line 518A and of the mela­
noma cell line IGR39D, which exhibits reduced HLA class I anti­
gen expression following transfection with the c-my' oncogene. 
Conversely, enhancement of HLA class I antigen expression in­
duced by incubation with IFN-)I was associated with a decrease in 
the susceptibility of IGR39D melanoma cells to NK cell-mediated 
lysis. Furthermore, we [29] have shown that the restoration ofHLA 
class I antigens in FO-1 melanoma cells after transfection with a 
wild-type B2m gene is associated with a statistically significant re­
duction in their susceptibility to NK. cell-mediated lysis. Incuba­
tion of transfected FO-1 cells with IFN-)I or TNF-a, which en­
hance the expression ofHLA class I antigens, although to a different 
extent, significandy reduced the NK. cell-mediated lysis of trans­
fected FO-1 cells. Surprisingly, TNF-a reduced the extent of lysis 
more than IFN-)l, although the latter cytokine enhanced the level of 
HLA class I antigens more than the former. These results suggest 
that the two cytokines reduce NK cell-mediated lysis of FO-1-
transfected melanoma cells by modulating not only the expression 
ofHLA class I antigens, but also other factor(s) that play a role in the 
phenomenon. This possibility is consistent with the observation 
that incubation with IFN-)I reduced the NK cell-mediated lysis of 
the melanoma cell line MELA, even though the level ofHLA class I 
antigens was not changed [30]. 
In a series of experiments to explore the non-immunologic role of 
HLA class I antigens in the economy of melanoma cells, we have 
analyzed the effect of a specific HLA class I antigen on the in vitro 
migration and adhesion properties of the melanoma cell line MM­
AN [31]. Expression of a transfected HLA-A2 gene was associated 
with a significant reduction in the in vitro migration of MM-AN 
cells and an enhancement of their adhesion properties (Fig 3). Fur­
thermore, the expression of HLA-A2 antigen affected the metasta­
sizing properties of MM-AN cells in severe combined immunodefi­
cjency (SCID) mice. Specifically, the cells that' expressed a 
. transfected HLA-A2 gene gave rise to a greater number of ovarian 
metastases, which were also remarkable for their very large size (Fig 
4). These studies confirm that the use of SCID mice (which are 
more immunodeficient than nude mice) provides a valuable model 
system to examine the in vivo metastatic potential of human mela­
noma cells [32]. Moreover, the incidence and remarkable size of the 
MM-AN -derived metastases suggest that certain melanoma cell 
lines may exhibit a tendency to colonize specific target organs 
where they may be able to grow quite rapidly. Because the expres­
sion of HLA-A2 antigen in MM-AN cells was associated with an 
enhanced ability to metastasize to the ovary of SCID mice, it is 
tempting to speculate that certain HLA class I antigens and specific 
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Figure 1. Effect of the expression of the transfected HLA-A2 gene on the 
migration of cultured human melanoma cells MM-AN. The HLA-A2 
gene subcloned in the EcoRI site of the vector pSV2-neo was generously 
provided by Dr. J.L. Strominger (Harvard UniveISity. Cambridge. MA). 
The resulting plasmid, pHLA-A2, contains the entire HLA-A2 genomic 
clone, including the regulatory sequences and is capable of conferring the 
neomycin-resistance phenotype to transfected cells. Exponentially grow­
ing MM-AN cell cultures were transfected with either pHLA-A2 or with 
pRSV-neo (carrying only the neomycin-resistance gene) using the cal­
cium phosphate precipitation technique. Neomycin-resistant clones from 
each set of transfections were pooled together and expanded. pHLA-A2 
transfectants were subjected to fluorescence-activated cell sorting using 
HLA-A2-specific MoAb MA2.1 to select the subpopulation of MM-AN 
transfectants expressing the HLA-A2 antigen. This subpopulation was 
compared to pRSV-neo transfectants (used as a control) in studies of cell 
migration in vitro. Thirty to forty cells per specimen were analyzed for 4 h 
using time-lapse video microscopy and migration patterns were mea­
sured by image analysis. • Statistically different from control (p < 0.001). 
growth factor receptors expressed by melanoma cells may interact 
on the cell surface, which will be discussed below. 
CONCLUSION 
The data we have summarized clearly indicate that malignant trans­
formation of melanocytes may be associated with abnormalities in 
HLA class I antigen expression. Using monoclonal antibodies recog­
nizing determinants shared by HLA-A, -B, and -C antigens, it has 
been conclusively shown that a complete loss of HLA class I anti­
gens may occur in about 30% of melanoma lesions. Furthermore, by 
using monoclonal antibodies specific for subsets of HLA class I 
antigens, it has been possible to document in melanoma cells the loss 
of expression of selected HLA class I loci (eg, HLA-B) and allospeci­
ficities (eg, HLA-A2). It is likely that by continuing to analyze 
melanoma cells with monoclonal antibodies displaying restricted 
reactivity for subsets of HLA class I antigens an increasing number 
of abnormalities will be found in melanoma lesions that exhibit no 
detectable changes in their reactivity with monoclonal antibodies 
recognizing determinants shared by HLA-A, -B, and -C antigens. 
An increasing number of studies is being carried out to define the 
molecular mechanisms underlying the abnormalities in HLA class I 
antigen expression by melanoma cells. These studies have already 
identified novel molecular defects in the human B2m gene and have 
allowed us to correct by DNA-mediated gene transfer, or by other 
means, the abnormalities that underlie the lack of HLA class I anti­
gen expression in certain melanoma cells lines. The available infor­
mation suggests that this type of study will be useful not only to 
define in molecular terms the changes in HLA class I antigen ex-
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Figure 4. Metastasis to the ovary in a SCID mouse of human melanoma 
cells MM-AN expressing the transfected HLA-A2 gene. The lower por­
tion of the micrograph shows that the tumor is composed of nests and 
cords of cells that exhibit abundant cytoplasm and pleomorphic. hyper­
chromatic nuclei. The upper portion of the micrograph shows two follicles 
embedded in ovarian stroma. Bar, 50 p.m. 
pression associated with malignant transformation of melanocytes, 
but may also contribute to the clarification of some of the regulatory 
mechanisms that control HLA class I antigen expression. 
Functional studies indicate that in melanoma, as in other malig­
nancies, HLA class I antigens restrict the interaction of melanoma 
cells with cytotoxic T cells recognizing tumor-associated antigens 
(for review, see [25,26]). On the other hand, the conflicting infor­
mation that is being obtained about the role ofHLA class I antigens 
in NK cell-mediated lysis of melanoma cells is likely to reflect the 
role of distinct variables that have been shown to influence this 
phenomenon. They include the density ofHLA class I antigens [33] 
and the specificity of HLA class I alloantigens expressed by target 
cells [34-36]. Among the models proposed for the mechanism un­
derlying the modulation ofNK cell-mediated lysis by HLA class I 
antigens (for review, see [12]), the one we favor postulates that HLA 
class I antigens and NK target structures from the same cell interact 
with each other, thus interfering with the interactions between 
target cells and NK cells. If so, one might suggest that the NK cell 
target structures expressed by various cell lines are different and that 
each type of NK cell target structure displays a differential reactivity 
with various HLA class I allospecificities. This interpretation is 
consistent with two lines of evidence: expression of different HLA 
class I allospecificities (achieved by DNA-mediated gene transfer) 
has a differential effect on the susceptibility of a cell line to NK 
cell-mediated lysis [34,35]. Conversely, expression of a transfected 
HLA class I gene may have a differential effect on the NK cell­
mediated lysis of different cell lines [34,36]. Furthermore, the lack 
of interaction because of low affinity between a given HLA class I 
allospecificity and the NK cell target structure expressed by a given 
cell line may be overcome by enhancing the expression of the HLA 
class I allospecificity. This possibility is supported by the report that 
target cells expressing a transfected HLA class I gene become less 
susceptible to NK cell-mediated lysis only following treatment 
with IFN-I', which enhances the expression of the newly acquired 
allospecificity [36]. 
With regard to the non-immunologic aspects of MHC-class I 
function in the regulation of cell proliferation and the malignant 
phenotype, it is tempting to speculate that HLA class I molecules 
associate themselves with cell surface structures like adhesion mole-
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cules or various growth factor receptors [37]. These associations 
may result in modulating the function of the cell surface molecules 
involved and consequently the proliferative capacity of malignant 
cells. In fact, it has been suggested that phosphorylated serine and 
tyrosine residues in the cytoplasmic domain of MHC class I heavy 
chain may be involved in phosphorylation of growth factor recep­
tors or otherwise modulate signal-transduction mechanisms con­
trolling cell division [8]. It will be interesting to see whether future 
molecular, biologic, and in vivo studies will support the concept of 
the very complex and multifaceted influence ofHLA-class I antigen 
expression on the malignant phenotype of human melanoma cells. 
This investigation was supported by PHS grant CA39559 awarded by the National 
Cancer Institute, DHHS. Dr. L. Calorini was supported by a fellowship from the 
Associazione Italiana per la Ricerca sui Cancro. We wish to thank Edwina L.Jones, 
Donna D. James, Gail D. Price, and Harriett V. Harrison for their excellent 
secretarial assistance. 
REFERENCES 
1. Poulik MD, Ferrone S, Pellegrino MA, Sevier DE, Oh SK, Reisfeld 
RA: Association of HL-A antigens and P2-microglobulin: concepts 
and questions. Transplant Proc 21:106, 1974 
2. Quaranta V, Walker LE, Ruberto G, Pellegrino MA, Ferrone S: The 
free and P2-microglobulin-associated heavy chains of HLA-A, B 
alloantigens share the antigenic determinant recognized by the 
monoclonal antibody Qlf28. Immunogenetics 13:285, 1981 
3. Temr0ni M, Kekish_UM, Wang Z, Ferrone S: Reactivity of monoclo­
na antibody (mAb) TP25.99 with a determinant shared by pz-mi­
croglobulin (P2-Jl.) associatedHLA-A, B and C heavy chains and P2-JI. 
free HLA-B and C heavy chains (submitted for publication) 
4. Mc Michael AJ: HLA restriction of human cytotoxic T cells. Springer 
Semin ImmunopathoI3:3, 1980 
5. Townsend A, Ohien C, Bastin J, Ljunggren HG, Foster L, Karle K: 
Association of class I histocompatibility heavy and light chains in­
duced by viral peptides. Nature 340:443,1989 
6. Turco MC, De Felice M, Corbo L, Morrone G, Mertelsmann R, 
Ferrone S, Venuta S: Regulatory role of a monomorphic determi­
nant of HLA class I antigens in T cell proliferation. J Immunol 
135:2268, 1985 
7. Gattoni-Celli S, Willett CJ, Rhoads DB, Simmon B, Sttauss RM, 
Kirsch K, Isselbacher KJ: Partial suppression of anchorage-indepen­
dent growth and tumorigenicity in immunodeficient mice by ttans­
fection of the H-2 class I gene H-2Ld into a human colon cancer cell 
line (HCT). Proc Nat! Acad Sci USA 85:8543, 1988 
8. Sunday ME, Isselbacher KJ, Gattoni-Celli S, Willett CG: Altered 
growth of a human neuroendocrine carcinoma line after ttansfec­
tion of a major histocompatibility complex class I gene. Proc Nat! 
Acad Sci USA 86:4700,1989 
9. Gattoni-Celli S, Strauss RM, Willett CG, Pozzatti R, Isselbacher KJ: 
Modulation of the transformed and neoplastic phenotype of rat fibro­
blasts by MHC-l gene expression. Cancer Res 49:3392,1989 
10. Gattoni-Celli S, Marozzi A, Timpane R, Kirsch K, Isselbacher KJ: 
Partial suppression of metastatic potential of malignant cells in im­
munodeficient mice caused by ttansfection of H-2Kb gene. J Nat! 
Cancer Inst 82:960, 1990 
11. Ljunggren H-G, Karre K: In search of the 'missing self ': MHC mole­
cules and NK cell recognition. Immunol Today 11:237, 1990 
12. Storkus WJ, Dawson JR: Target structures involved in natural killing 
(NK): characteristics, distribution, and candidate molecules. Crit 
Rev Immunol l0:393, 1991 
13. Ferrone S, Imberti L, Natali PG, Schrier PI, Ruiter OJ: HLA antigens 
on tumor cells. In: Roth JA (ed.). Monoclonal Antibodies in Cancer: 
Advances in Diagnosis and Treatment. Futura Publishing Com­
pany, New York, 1986, p 111 
14. van den Ingh HF, Ruiter OJ, Griffioen G, van Muijen GNP, Ferrone S: 
HLA antigens in colorectal tumours-low expression of HLA class I 
antigens in mucinous colorectal carcinomas. Br J Cancer 55:125, 
1987 
15. van Duinen SG, Ruiter OJ, Broecker EB, van der Velde EA, Sorg C, 
Welvaart K, Ferrone S: Level of HLA antigens in locoregional me-
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
tastases and clinical course of the disease in patients with melanoma. 
Cancer Res 48:1019, 1988 
16. Ruiter OJ, Mattijssen V, Broecker E-B, Ferrone S: MHC antigens in 
human melanomas. Semin Cancer Bioi 2:35, 1991 
17. Natali PG, Bigotti A, Cavalieri R, Nicotta MR, Tecce R, Manfredi 0, 
Chen Y-X, Nadler LM, Ferrone S: Gene products of the HLA-D 
region in normal and malignant tissues of nonlymphoid origin. 
Hum ImmunoI15:220, 1986 
18. van Duinen SG, Ruiter OJ, Ferrone S: Associated expression of HLA 
Class I and Class II antigens on melanoma cells in surgically re­
moved metastases. J PathoI149:339, 1986 
19. D'Urso CM, Wang Z, Cao Y, Tatake R, Zeff RA, Ferrone S: Lack of 
HLA class I antigen expression by cultured melanoma cells FO-l 
due to a defect in Bzm gene expression. J Clin Invest 87:284, 1991 
20. Wang Z, Cao Y, Albino AP, ZeffRA, Houghton A, Ferrone S: Lack of 
HLA class I antigen expression by melanoma cell SK-MEL-33 caused 
by a reading frameshift in P2-JI. mRNA. J Clin Invest (in press) 
21. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, 
Wiley DC: Structure of the human class I histocompatibility anti­
gen, HLA-A2. Nature 329:506, 1987 
22. Versteeg R, Kruse-Wolters KM, Plomp AC, van Leeuwen A, Starn NJ, 
Ploegh HL, Ruiter OJ, Schrier PI: Suppression of class I human 
histocompatibility leukocyte antigen by c-myc is locus specific. J 
Exp Med 170:621, 1989 
23. Natali PG, Nicotra MR, Bigotti A, Venturo I, Marcenaro L, Giacomini 
P, �usso C: �electi�e changes in.
expression of HLA class I polymor­
phic detenmnants m human sohd tumors. Proc Nat! Acad Sci USA 
86:6719, 1989 
24. Pandolfi F, Boyle LA, Trentin L, Kurnick JT, Isselbacher KJ, Gattoni­
Celli S: Expression of HLA-A2 antigen in human melanoma cell 
lines and its role in T-cell recognition. Cancer Res 51:3164, 1991 
25. Mukherji B, Chakraborty NG, Sivanandham M: T-cell clones that 
react against autologous human tumors. Immunol Rev 116:33, 1990 
26. Platsoucas CD: Human autologous tumor-specific T cells in malignant 
melanoma. Cancer Metastasis Rev 10:151, 1991 
27. Lobo PI, Spencer CE: Use of anti-HLA antibodies to mask major 
histocompatibility complex gene products on tumor cells can en­
hance susceptibility of these cells to lysis by natural killer cells. J Clin 
Invest 83:278-287, 1989 
28. Versteeg R, Peltenburg LTC, Plomp AC, Schrier PI: High expression 
of the c-myc oncogene renders melanoma cells prone to lysis by 
natural killer cells. J ImmunoI143:4331-4337, 1989 
29. Maio M, Altomonte M, Tatake R, Zeff RA, Ferrone S: Reduction in 
susceptibility to natural killer cell-mediated lysis of human FO-l 
melanoma cells after induction of HLA class I antigen expression by 
transfection with B2m gene. J Clin Invest 88:282, 1991 
30. Pena J, Alonso C, Solana R, Serrano R, Carracedo J, Ramirez R: 
Natural killer susceptibility is independent of HLA class I antigen 
expression on cell lines obtained from human solid tumors. Eur J 
ImmunoI20:2445,1990 
31. Byers HR, Etoh T, Doherty JR, Sober AJ, MihmJr MC: Cell migra­
tion and actin organization in cultured human primary, recurrent 
cutaneous and metastatic melanoma. Time-lapse and image analysis. 
Am J PathoI139:423, 1991 
32. Mueller BM, Romerdahl CA, Trent JM, Reisfeld RA: Suppression of 
spontaneous melanoma metastasis in SCID mice with an antibody to 
the epidermal growth factor receptor. Cancer Res 51:2193, 1991 
33. Storkus WJ, Alexander J, Payne JA, Dawson JR, Cresswell P: Reversal 
of natural killing susceptibility in target cells expressing transfected 
class I HLA genes. Proc Nat! Acad Sci USA 86:2361, 1989 
- 34. Storkus WJ, Alexander J, Payne JA, Cresswell P, Dawson JR: The 
alf a2 domains of class I HLA molecules confer resistance to natural 
killing. J ImmunoI143:3853, 1989 
35. Shimizu Y, DeMars R: Demonstration by class I gene transfer that 
reduced susceptibility of human cells to natural killer cell-mediated 
lysis is inversely correlated with HLA class I antigen expression. Eur 
J ImmunoI19:447, 1989 
36. Maziarz RT, Mentzer SJ, Burakoff SJ, Faller DV: Distinct effects of 
interferon-l' and MHC class I surface antigen levels on resistance of 
the K562 tumor cell line to natural killer-mediated lysis. Cell Im­
munol 130:329, 1990 
37. Haliotis T, Carlow DA, Elliott BE: Non-immunological aspects of 
MHC function in the regulation of cell proliferation and the malig­
nant phenotype. Cancer Cells 2:86, 1990 
